USAID has pumped $45 million in grant funding to support the work of a consortium of top African scientists from eight countries
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
Gray is the first female president and chief executive of the council and served as the chairperson of the research committee on Covid-19
The coronavirus pandemic, and ensuing variants, mean we can’t make plans without the prospect of last-minute cancellations. But there’s precious little we can do about it
Staff and students argue it is unethical for university to profit from an industry that damages the planet and distorts science
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
Increasing seroprevalence in South Africa could help curb the disastrous effects a third wave could have on communities. But no one is out of the woods yet
This has resulted in demand exceeding supply — or vice versa — at many vaccination sites
Although the country got off to a slow start, experts are hopeful SA’s Covid-19 inoculation drive will scale up soon
A high efficacy rate for a single-dose J&J/Janssen Covid-19 vaccine might help to speed up the much-needed roll-out plan
Private doctors and civilians have been exploiting gaps in the public health system to get vaccinated
Health Minister Zweli Mkhize says selling on the vaccines will stem wasteful expenditure, but people close to the discussions with AU say they will be sold on the cheap
This content is restricted to subscribers only.
Join the M&G Community
Our commitment at the Mail & Guardian is to ensure every reader enjoys the finest experience. Join the M&G community and support us in delivering in-depth news to you consistently.
Subscribe
Subscription enables:
- – M&G community membership
- – independent journalism
- – access to all premium articles & features
- – a digital version of the weekly newspaper
- – invites to subscriber-only events
- – the opportunity to test new online features first
Already a subscriber?
Login here.
Eighty thousand Johnson & Johnson jabs will arrive in South Africa on Tuesday and be taken to 16 sites where healthcare workers will be vaccinated
We spoke to experts, looked at the data and relistened to the health department’s briefings to break down the revised roll-out plan
SA’s one-million doses of the AstraZeneca vaccine will expire by early April — unless India’s Serum Institute can safely extend their use-by date.
UKZN researchers argue that government clinics should stop providing free formula milk to all HIV-infected mothers.
No image available
/ 22 January 2008
Researchers from the University of Cape Town have developed two test HIV vaccines — the first wholly South African-developed products to enter the human clinical-trials phase, the Herald Online reported on Tuesday. The vaccines are just months away from being assessed in human clinical trials, the report said.
No image available
/ 14 November 2007
All HIV vaccine trials in South Africa have been put on hold following the failure of the Phambili trial. Health Minister Manto Tshabalala-Msimang on Wednesday invited researchers who worked on the Phambili study to her office in Pretoria to explain the reasons why the vaccine trial was stopped.
No image available
/ 23 September 2007
The supervisor of a major HIV vaccine trial in South Africa voiced ”huge disappointment” on Saturday after testing was halted in the wake of poor results from sister trials in Australia and the United States. US pharmaceutical giant Merck announced on Friday that it had halted the trials of its V520 vaccine.
No image available
/ 22 September 2007
A major HIV vaccine trial in South Africa was brought to a halt on Friday after interim results from a sister trial in the United States and Australia suggested it failed to prevent HIV infection. The news came as a major blow to Aids researchers as the vaccine had been billed as the world’s most promising Aids-vaccine candidate.
Parallel trials for Aids vaccines in South Africa look promising in their long road to conclusion, a press conference in Sandton heard on Friday. Indications are that vaccine trials tailored for global strains had an effect against the strain of the virus most prevalent in South Africa.
Naeemah Abrahams, Miriam Adhikari, Carol-Ann Benn, Francesca Conradie, Lynette Denny, Sharon Ekambaram, Sharon Fonn and more …